Les publications dans les journaux scientifiques par les membres du réseau reflètent la productivité de la recherche CRISALIS. Voici quelques chiffres :
Retrouvez ci-dessous les principales publications des membres CRISALIS (auteurs notés en gras) dans le domaine de l'asthme sévère, par année, depuis la création du réseau.
⚠️ Il ne s'agit pas d'une liste exhaustive mais d'un aperçu d'une dizaine de publications par an.
2026
Cliquez ici pour retrouver les dernières publications asthme sévère des membres CRISALIS
2025
| Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage. Porsbjerg C, Rupani H, Brannan JD, Ueki S, Nawijn MC, Erjefält JS, Chanez P, Anderson GP, Pavord ID. Lancet Respir Med. 2025 Nov;13(11):1026-1040. doi: 10.1016/S2213-2600(25)00299-1. Epub 2025 Sep 29. PMID: 41038212 Review. |
| Exploring the Diversity and Emerging Powers of Eosinophil Subpopulations. Ecrement A, Spasovski V, Rolin G, Barnig C. Allergy. 2025 Nov;80(11):3012-3026. doi: 10.1111/all.16631. Epub 2025 Jun 26. PMID: 40568764 Review. |
| Long-term effectiveness and safety of dupilumab in severe asthma: A 5-year real-world multicenter study. Chauvin A, Belhadi D, Dupin C, Guilleminault L, Boudjemaa A, Ghourabi N, Gamez AS, Berger P, Khayat N, Bonniaud P, Leroyer C, Mahay G, Fry S, Girodet PO, Le Bourdellès G, Proust A, Rosencher L, Garcia G, Bourdin A, Chenivesse C, Didier A, Couffignal C, Taillé C. J Allergy Clin Immunol Pract. 2025 Sep;13(9):2515-2517.e2. doi: 10.1016/j.jaip.2025.05.050. Epub 2025 Jun 4. PMID: 40480546 |
| Diagnosis of Dysfunctional Breathing in Severe Asthma. Soumagne T, Garcia G, Frija J, Chenivesse C, Perez T, Plantier L, Humbert M, Laveneziana P, Beurnier A, Taillé C, Degano B. J Allergy Clin Immunol Pract. 2025 Aug;13(8):2052-2059.e5. doi: 10.1016/j.jaip.2025.04.033. Epub 2025 Apr 29. PMID: 40312009 |
| Factitious severe asthma: A diagnostic challenge in the era of biologics. Larhant C, Lassus A, Morelot-Panzini C, Taupinard E, Geoffroy PA, Taillé C. J Allergy Clin Immunol Pract. 2025 May;13(5):1228-1230. doi: 10.1016/j.jaip.2025.02.008. Epub 2025 Feb 18.PMID: 39978546 |
| Bronchial wall T2w MRI signal as a new imaging biomarker of severe asthma. Benlala I, Dournes G, Girodet PO, Laurent F, Ben Hassen W, Baldacci F, De Senneville BD, Berger P. Insights Imaging. 2025 Mar 25;16(1):71. doi: 10.1186/s13244-025-01939-1. PMID: 40133719 |
| Rheumatic adverse effects with biologics targeting type 2 inflammation in severe asthma: A VigiBase study. Laux M, Montastruc F, Degboe Y, Guilleminault L. J Allergy Clin Immunol Pract. 2025 Jan;13(1):225-227.e1. doi: 10.1016/j.jaip.2024.09.029. Epub 2024 Oct 4. PMID: 39369854 |
| Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps. Tiotiu A, Migueres N, Gonzalez-Barcala FJ, Roux P, Oster JP, Moutard N, de Blay F, Bonniaud P. Respir Med. 2025 Mar;238:107979. doi: 10.1016/j.rmed.2025.107979. Epub 2025 Jan 31. PMID: 39894084 |
| Long-acting muscarinic antagonists (LAMA) in asthma: What is the best strategy? Mahay G, Zysman M, Guibert N, Barnig C, Guilleminault L, Dupin C. Respir Med Res. 2025 May;87:101157. doi: 10.1016/j.resmer.2025.101157. Epub 2025 Jan 31. PMID: 39946978. Review. |
| [Emergency room visits for asthma and the reported outcomes: The PASS survey by the CRISALIS network]. Didier A, Camus C, Lemeur A, Bieler L, Rudzky C, Barnig C, Dussaucy A, Beurnier A, Nguyen Quang JM, Blanc FX, Kenzi A, Bonniaud P, Baptiste N, Bourdin A, Sebbane M, Chanez P, Pahus L, Devouassoux G, Labeye V, Khayath N, Raherison-Semjen C, Saint Raymond C, Taillé C, Ghazali DA, Boulay V, Souab A, Delpire P, Verdière CH, Fouquet H, Gazaille V, Maurer C, Petit L, Portel L, Girard A, Proust A, Rochefort-Morel C, Le Lan-Schnell AL, Guilleminault L. Rev Mal Respir. 2025 Oct;42(8):387-393. doi: 10.1016/j.rmr.2025.06.006. Epub 2025 Jul 24. PMID: 40713267 French. |
2024
| Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators 💥. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. PMID: 38071986 Clinical Trial. |
| Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series. Dupin C, Valéry S, Guilleminault L, Devouassoux G, Merveilleau M, Russier M, Mourin G, Pradelli J, Bonniaud P, Le Brun M, Ebstein E, Juge PA, Lillo-Lelouet A, Taillé C. ERJ Open Res. 2024 Feb 26;10(1):00935-2023. doi: 10.1183/23120541.00935-2023. eCollection 2024 Jan. PMID: 38410709 |
| Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group 💥. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. PMID: 38393328 Clinical Trial. |
| Severe asthma care trajectories: the French RAMSES cohort. Perotin JM, Gauquelin L, Just N, Devouassoux G, Chenivesse C, Bourdin A, Garcia G, Saint Raymond C, Boudjemaa A, Bonniaud P, Chanez P, Barnig C, Beurnier A, Maurer C, Freymond N, Didi T, Tcherakian C, Russier M, Drucbert M, Guillo S, Estellat C, Taillé C. ERJ Open Res. 2024 Apr 22;10(2):00837-2023. doi: 10.1183/23120541.00837-2023. eCollection 2024 Mar. PMID: 38651091 |
| Asthma loss of control after switch from anti-IL-5/5R drugs to dupilumab in severe eosinophilic asthma: A case series. Poisson C, Chenivesse C, Cuvillon E, Barnig C, Clarot C, Dupin C, Mangiapan G, Rolland-Debord C, Bonniaud P, Taillé C. J Allergy Clin Immunol Pract. 2024 Jul;12(7):1914-1917. doi: 10.1016/j.jaip.2024.03.037. Epub 2024 Mar 27. PMID: 38553004 |
| Imagining the severe asthma decision trees of the future. Bourdin A, Bardin P, Chanez P. Expert Rev Respir Med. 2024 Aug;18(8):561-567. doi: 10.1080/17476348.2024.2390987. Epub 2024 Aug 20. PMID: 39120156 Review. |
| Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trial. Valery S, Simon-Tillaux N, Devouassoux G, Bonniaud P, Beurnier A, Boudjemaa A, Chenivesse C, Bourdin A, Gauquelin L, Guillo S, Taillé C, Estellat C; RAMSES Study Group. J Allergy Clin Immunol. 2024 Oct;154(4):922-932. doi: 10.1016/j.jaci.2024.05.023. Epub 2024 Jun 6. PMID: 38848878 Clinical Trial. |
| Efficacy of bronchial thermoplasty in patients with severe asthma and frequent severe exacerbations: A randomized controlled study✰. Leroux J, Khayath N, Matau C, Marcot C, Migueres N, Barnig C, Molard A, Ochea D, Ohana M, Lefebvre F, de Blay F. Respir Med Res. 2024 Nov;86:101109. doi: 10.1016/j.resmer.2024.101109. Epub 2024 Apr 17. PMID: 38875851 Clinical Trial. |
| Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID; SWIFT-1 and SWIFT-2 Investigators 💥; SWIFT-1 Investigators; SWIFT-2 Investigators. N Engl J Med. 2024 Dec 19;391(24):2337-2349. doi: 10.1056/NEJMoa2406673. Epub 2024 Sep 9. PMID: 39248309 Clinical Trial. |
| Allergen Immunotherapy for the Prevention and Treatment of Asthma. Batard T, Taillé C, Guilleminault L, Bozek A, Floch VB, Pfaar O, Canonica WG, Akdis C, Shamji MH, Mascarell L. Clin Exp Allergy. 2025 Feb;55(2):111-141. doi: 10.1111/cea.14575. Epub 2024 Oct 4. PMID: 39363801 Review. |
💥 Membres CRISALIS inclus dans "SHAMAL investigators" : Pr G. Devouassoux, Pr M. Humbert, Pr P. Bonniaud, Dr G. Beltramo, Pr PO. Girodet, Pr P. Berger
💥 Membres CRISALIS inclus dans "MANDARA Study Group " : Pr C. Taillé, Pr A. Bourdin, Pr P. Chanez, Pr C. Tchérakian
💥 Membres CRISALIS inclus dans "SWIFT-1 and SWIFT-2 Investigators" : Pr P. Chanez, Pr A. Bourdin, Dr PM. Roux
2023
| Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab. Pereira S, Verhille J, Cailliau E, Bonniaud P, Devouassoux G, Fry S, Guilleminault L, Khayath N, Leroyer C, Chenivesse C, Bautin N. Clin Exp Allergy. 2023 Dec;53(12):1298-1301. doi: 10.1111/cea.14392. Epub 2023 Sep 13. PMID: 37705326 |
| Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study. Guilleminault L, Camus C, Raherison-Semjen C, Capdepon A, Bourdin A, Bonniaud P, Fry S, Devouassoux G, Blanc FX, Pison C, Dupin C, Khayath N, Courdeau J, Valcke-Brossollet J, Nocent-Ejnaini C, Rolland F, Lamandi C, Proust A, Ozier A, Portel L, Gaspard W, Roux-Claude P, Beurnier A, Martinez S, Dot JM, Hennegrave F, Vignal G, Auvray E, Paleiron N, Just N, Miltgen J, Russier M, Olivier C, Taillé C, Didier A. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231202749. doi: 10.1177/17534666231202749. PMID: 37966015 |
| Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective. Levy ML, Bateman ED, Allan K, Bacharier LB, Bonini M, Boulet LP, Bourdin A, Brightling C, Brusselle G, Buhl R, Chakaya MJ, Cruz AA, Drazen J, Ducharme FM, Duijts L, Fleming L, Inoue H, Ko FWS, Krishnan JA, Masekela R, Mortimer K, Pitrez P, Salvi S, Sheikh A, Reddel HK, Yorgancıoğlu A. Lancet. 2023 Sep 16;402(10406):1012-1016. doi: 10.1016/S0140-6736(23)01358-2. Epub 2023 Jul 19. PMID: 37480934 Review. |
| Benralizumab for eosinophilic granulomatosis with polyangiitis. Cottu A, Groh M, Desaintjean C, Marchand-Adam S, Guillevin L, Puechal X, Beaumesnil S, Lazaro E, Samson M, Taille C, Durel CA, Diot E, Nicolas S, Guilleminault L, Ebbo M, Cathebras P, Dupin C, Yildiz H, Belfeki N, Pugnet G, Chauvin P, Jouneau S, Lifermann F, Martellosio JP, Cottin V, Terrier B; French Vasculitis Study Group. Ann Rheum Dis. 2023 Dec;82(12):1580-1586. doi: 10.1136/ard-2023-224624. Epub 2023 Aug 7. PMID: 37550002 |
| Eosinophils and tissue remodeling: Relevance to airway disease. Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, Rupani H, Sagara H, Howarth P, Taillé C. J Allergy Clin Immunol. 2023 Oct;152(4):841-857. doi: 10.1016/j.jaci.2023.06.005. Epub 2023 Jun 19. PMID: 37343842 Review. |
| Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose. Pavord ID, Bourdin A, Papi A, Domingo C, Corren J, Altincatal A, Radwan A, Pandit-Abid N, Jacob-Nara JA, Deniz Y, Rowe PJ, Laws E, Lederer DJ, Hardin M. Allergy. 2023 Nov;78(11):2921-2932. doi: 10.1111/all.15792. Epub 2023 Jul 11. PMID: 37431558 |
| Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy. Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. PMID: 36948488 |
| Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps. Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7. PMID: 36356712 |
| Onset of eosinophilic granulomatosis with polyangiitis (EGPA) after anti-Th2 biotherapy initiation in severe asthma patients: Report of 3 cases. Fargeas M, Devouassoux G, Gerfaud-Valentin M. Respir Med Res. 2023 Nov 30;85:101070. doi: 10.1016/j.resmer.2023.101070. Online ahead of print. PMID: 38141578 |
| Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma. Menigoz C, Dirou S, Chambellan A, Hassoun D, Moui A, Magnan A, Blanc FX. J Asthma. 2023 Jun;60(6):1162-1170. doi: 10.1080/02770903.2022.2136526. Epub 2022 Nov 15. PMID: 36301080 |
| Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations. Melscoet L, Khayath N, Migueres N, Goltzene MA, Meyer N, de Blay F. J Asthma. 2023 May;60(5):881-889. doi: 10.1080/02770903.2022.2103427. Epub 2022 Aug 11. PMID: 35862624 |
2022
| Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, Smith SG, Martin N, Gilson MJ, Price RG, Bradford ES, Liu MC. Eur Respir J. 2022 Jan 6;59(1):2100396. doi: 10.1183/13993003.00396-2021. Print 2022 Jan. PMID: 34172470 |
| Vulnerability to acid reflux of the airway epithelium in severe asthma. Perotin JM, Wheway G, Tariq K, Azim A, Ridley RA, Ward JA, Schofield JPR, Barber C, Howarth P, Davies DE, Djukanovic R. Eur Respir J. 2022 Aug 4;60(2):2101634. doi: 10.1183/13993003.01634-2021. Print 2022 Aug. PMID: 34996831 |
| Rhinovirus infection of bronchial epithelium induces specific bronchial smooth muscle cell migration of severe asthmatic patients. Celle A, Esteves P, Cardouat G, Beaufils F, Eyraud E, Dupin I, Maurat E, Lacomme S, Ousova O, Begueret H, Thumerel M, Marthan R, Girodet PO, Berger P, Trian T. J Allergy Clin Immunol. 2022 Jul;150(1):104-113. doi: 10.1016/j.jaci.2022.01.022. Epub 2022 Feb 7. PMID: 35143808 |
| Multifocal bronchial stenosis and extensive lobar atelectasis as a rare radiologic feature of severe eosinophilic asthma. Phillips-Houlbracq M, Debray MP, Guyard A, Khoury R, Dombret MC, Le Brun M, Deneuville L, Dupin C, Taillé C. J Allergy Clin Immunol Pract. 2023 Jan;11(1):341-343.e1. doi: 10.1016/j.jaip.2022.10.004. Epub 2022 Oct 18. PMID: 36265767 |
| Asthmatic bronchial smooth muscle increases rhinovirus replication within the bronchial epithelium. Esteves P, Allard B, Celle A, Dupin I, Maurat E, Ousova O, Thumerel M, Dupuy JW, Leste-Lasserre T, Marthan R, Girodet PO, Trian T, Berger P. Cell Rep. 2022 Mar 29;38(13):110571. doi: 10.1016/j.celrep.2022.110571. PMID: 35354045 |
| Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Heatley H, Tran TN, Bourdin A, Menzies-Gow A, Jackson DJ, Maslova E, Chapaneri J, Skinner D, Carter V, Chan JSK, Ariti C, Haughney J, Price DB. Thorax. 2022 Dec 27:thorax-2022-219642. doi: 10.1136/thorax-2022-219642. Online ahead of print. PMID: 36575040 |
| Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps. Tiotiu A, Mendez-Brea P, Ioan I, Romero-Fernandez R, Oster JP, Hoang TC, Roux P, Ochoa-Gutierrez DC, Bonniaud P, de Blay F, Gonzalez-Barcala FJ. Clin Rev Allergy Immunol. 2022 Apr 14. doi: 10.1007/s12016-022-08938-w. Online ahead of print. PMID: 35420388 |
| Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial. Davidescu L, Ursol G, Korzh O, Deshmukh V, Kuryk L, Nortje MM, Godlevska O, Devouassoux G, Khodosh E, Israel E, Moussy A, Mansfield CD, Hermine O, Chanez P. J Asthma Allergy. 2022 Jun 7;15:737-747. doi: 10.2147/JAA.S337284. eCollection 2022. PMID: 35698580 |
| De-labelling severe asthma diagnosis: the challenge of DIPNECH. Hurabielle C, Taillé C, Prévot G, Russier M, Didier A, Girodet PO, Colombat M, Mazières J, Guilleminault L. ERJ Open Res. 2022 Feb 7;8(1):00485-2021. doi: 10.1183/23120541.00485-2021. eCollection 2022 Jan. PMID: 35211620 |
| Phenotyping to Target Obstructive Sleep Apnoea Syndrom (OSAS) in adults patients with severe asthma. Portel L, Parrat E, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, de Vecchi CA, Maurer C, Raherison C, Debieuvre D. Respir Med Res. 2022 Nov;82:100888. doi: 10.1016/j.resmer.2022.100888. Epub 2022 Feb 3. PMID: 35691215 |
2021
|
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. PMID: 33979488 |
|
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. Adir Y, Humbert M, Saliba W. J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15. PMID: 34144110 |
|
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, Garcia Gil E. Allergy. 2022 Jan;77(1):150-161. doi: 10.1111/all.14902. Epub 2021 Jun 8. PMID: 33978983 |
|
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, Liu MC, Martin N, Papi A, Roufosse F, Steinfeld J, Wechsler ME, Yancey SW. Allergy. 2022 Mar;77(3):778-797. doi: 10.1111/all.15056. Epub 2021 Sep 16. PMID: 34402066 |
|
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-2714. doi: 10.1016/j.jaip.2021.01.011. Epub 2021 Jan 21. PMID: 33486142 |
|
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4381-4392.e4. doi: 10.1016/j.jaip.2021.07.058. Epub 2021 Sep 4. PMID: 34487870 |
|
Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. Dilasser F, Rose L, Hassoun D, Klein M, Rousselle M, Brosseau C, Guignabert C, Taillé C, Dombret MC, Di Candia L, Heddebaut N, Bouchaud G, Pretolani M, Magnan A, Loirand G, Sauzeau V. Thorax. 2021 Apr;76(4):326-334. doi: 10.1136/thoraxjnl-2020-216271. Epub 2021 Feb 4. PMID: 33542087 |
|
FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis. Raherison-Semjen C, Parrat E, Nocent-Eijnani C, Mangiapan G, Prudhomme A, Oster JP, Aperre de Vecchi C, Maurer C, Debieuvre D, Portel L; CPHG (College of French Non-academic Hospitals). Respir Res. 2021 May 4;22(1):136. doi: 10.1186/s12931-021-01723-x. PMID: 33947403 |
|
Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. Just J, Thonnelier C, Bourgoin-Heck M, Mala L, Molimard M, Humbert M; STELLAIR Investigators. J Asthma Allergy. 2021 Sep 23;14:1129-1138. doi: 10.2147/JAA.S310888. eCollection 2021. PMID: 34588784 |
|
Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study. Mattei L, Suehs CM, Alagha K, Bourdin A, Brousse C, Charriot J, Devouassoux G, Fry S, Guilleminault L, Gouitaa M, Taille C, Chanez P, Pahus L. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049735. doi: 10.1177/17534666211049735. PMID: 34629000 |
|
Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Descamps V, Deschamps L, El Khalifa J, Groh M, Gibier JB, Lefèvre G, Taillé C. Respir Med Res. 2021 May;79:100821. doi: 10.1016/j.resmer.2021.100821. Epub 2021 Apr 28. PMID: 33984814 |
2020
|
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. PMID: 33357499 |
|
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Bachert C, Humbert M, Hanania NA, Zhang N, Holgate S, Buhl R, Bröker BM. Eur Respir J. 2020 Apr 3;55(4):1901592. doi: 10.1183/13993003.01592-2019. Print 2020 Apr. PMID: 31980492 |
|
Aberrant anti-viral response of natural killer cells in severe asthma. Devulder J, Chenivesse C, Ledroit V, Fry S, Lobert PE, Hober D, Tsicopoulos A, Duez C. Eur Respir J. 2020 May 14;55(5):1802422. doi: 10.1183/13993003.02422-2018. Print 2020 May. PMID: 32108047 |
|
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Taillé C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, Charriot J, Bouée S, Gruber A, Pribil C, Bourdin A, Humbert M. Eur Respir J. 2020 Jun 25;55(6):1902345. doi: 10.1183/13993003.02345-2019. Print 2020 Jun. PMID: 32241829 |
|
Type 2-high asthma is associated with a specific indoor mycobiome and microbiome. Vandenborght LE, Enaud R, Urien C, Coron N, Girodet PO, Ferreira S, Berger P, Delhaes L. J Allergy Clin Immunol. 2021 Apr;147(4):1296-1305.e6. doi: 10.1016/j.jaci.2020.08.035. Epub 2020 Sep 12. PMID: 32926879 |
|
Will the asthma revolution fostered by biologics also benefit adult ICU patients? Bourdin A, Charriot J, Boissin C, Ahmed E, Suehs C, De Sevin A, Volpato M, Pahus L, Gras D, Vachier I, Halimi L, Hamerlijnck D, Chanez P. Allergy. 2021 Aug;76(8):2395-2406. doi: 10.1111/all.14688. Epub 2020 Dec 26. PMID: 33283296 |
|
SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, Fraisse P, Tu Hoang TC, Kassegne L, Labani A, Leyendecker P, Manien L, Marcot C, Pamart G, Renaud-Picard B, Riou M, Doyen V, Kessler R, Fafi-Kremer S, Metz-Favre C, Khayath N, de Blay F. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2600-2607. doi: 10.1016/j.jaip.2020.06.032. Epub 2020 Jun 27. PMID: 32603901 |
|
How can we minimise the use of regular oral corticosteroids in asthma? Bourdin A, Adcock I, Berger P, Bonniaud P, Chanson P, Chenivesse C, de Blic J, Deschildre A, Devillier P, Devouassoux G, Didier A, Garcia G, Magnan A, Martinat Y, Perez T, Roche N, Taillé C, Val P, Chanez P. Eur Respir Rev. 2020 Feb 5;29(155):190085. doi: 10.1183/16000617.0085-2019. Print 2020 Mar 31. PMID: 32024721 |
|
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, Bonniaud P, Leroyer C, Mahay G, Girodet PO, Raherison C, Fry S, Le Bourdellès G, Proust A, Rosencher L, Garcia G, Bourdin A, Chenivesse C, Didier A, Couffignal C, Taillé C. Clin Exp Allergy. 2020 Jul;50(7):789-798. doi: 10.1111/cea.13614. Epub 2020 May 29. PMID: 32469092 Clinical Trial. |
|
Global Quality Standard for Identification and Management of Severe Asthma. Haughney J, Winders TA, Holmes S, Chanez P, Saul H, Menzies-Gow A; PRECISION Improve Access to Better Care Task Force. Adv Ther. 2020 Sep;37(9):3645-3659. doi: 10.1007/s12325-020-01450-7. Epub 2020 Jul 28. PMID: 32725419 |
|
Is CCL18 a potential biomarker of type-2 asthma endotypes? Fouquet H, Giovannelli J, de Nadaï P, Balsamelli J, Berger P, Bourdin A, Chanez P, Fry S, Perez T, Magnan A, Pretolani M, Taillé C, Tsicopoulos A, Chenivesse C; COBRA study group. J Asthma. 2022 Mar;59(3):536-540. doi: 10.1080/02770903.2020.1861623. Epub 2020 Dec 18. PMID: 33287605 |
2019
|
Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Pahus L, Jaffuel D, Vachier I, Bourdin A, Suehs CM, Molinari N, Chanez P. Eur Respir J. 2019 Feb 7;53(2):1802187. doi: 10.1183/13993003.02187-2018. Print 2019 Feb. PMID: 30759420 |
|
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Albers FC, Hozawa S, Bratton DJ, Yancey SW, Prazma CM, Humbert M, Liu MC. Allergy. 2020 Apr;75(4):942-946. doi: 10.1111/all.14048. Epub 2019 Oct 2. PMID: 31520471 |
|
Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma. Granger V, Taillé C, Roach D, Letuvé S, Dupin C, Hamidi F, Noël B, Neukirch C, Aubier M, Pretolani M, Chollet-Martin S, de Chaisemartin L. Allergy. 2020 Mar;75(3):699-702. doi: 10.1111/all.14059. Epub 2019 Oct 24. PMID: 31549729 |
|
Serum IgG Concentrations in Adult Patients Experiencing Virus-Induced Severe Asthma Exacerbations. Verduyn M, Botto G, Jaubert J, Lier C, Flament T, Guilleminault L. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1507-1513.e1. doi: 10.1016/j.jaip.2018.12.028. Epub 2019 Jan 14. PMID: 30654200 |
|
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database. Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, Laurendeau C, Bureau I, Gourmelen J, Chouaid C. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1477-1487. doi: 10.1016/j.jaip.2018.12.029. Epub 2019 Jan 25. PMID: 30685573 |
|
Severe Occupational Asthma: Insights From a Multicenter European Cohort. Vandenplas O, Godet J, Hurdubaea L, Rifflart C, Suojalehto H, Walusiak-Skorupa J, Munoz X, Sastre J, Klusackova P, Moore V, Merget R, Talini D, Kirkeleit J, Mason P, Folletti I, Cullinan P, Moscato G, Quirce S, Hoyle J, Sherson D, Kauppi P, Preisser A, Meyer N, de Blay F; European network for the PHenotyping of OCcupational ASthma (E-PHOCAS) investigators. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2309-2318.e4. doi: 10.1016/j.jaip.2019.03.017. Epub 2019 Mar 23. PMID: 30914232 |
|
Evaluation in a severe asthma expert center improves asthma outcomes regardless of step-up in asthma therapy. Bègne C, Justet A, Dupin C, Taillé C. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1439-1442.e2. doi: 10.1016/j.jaip.2019.10.026. Epub 2019 Nov 6. PMID: 31706047 |
|
International Severe Asthma Registry: Mission Statement. ISAR Study Group 💥. Chest. 2020 Apr;157(4):805-814. doi: 10.1016/j.chest.2019.10.051. Epub 2019 Dec 12. PMID: 31838187 |
|
Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study. Tiotiu A, Oster JP, Roux PR, Nguyen Thi PL, Peiffer G, Bonniaud P, Dalphin JC, de Blay F. J Investig Allergol Clin Immunol. 2020;30(1):49-57. doi: 10.18176/jiaci.0391. Epub 2019 Apr 1. PMID: 30931917 |
|
Severe asthma treated by bronchial thermoplasty: A success not due to the small airways? Chanez P, Pahus L, Charriot J, Bourdin A. Respirology. 2019 May;24(5):402-403. doi: 10.1111/resp.13481. Epub 2019 Jan 29. PMID: 30694006 |
💥 Membre CRISALIS inclus dans le "ISAR study group" : Pr A. Bourdin
2018
|
Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Humbert M. Lancet Respir Med. 2018 Jan;6(1):7-8. doi: 10.1016/S2213-2600(17)30343-0. Epub 2017 Sep 11. PMID: 28919199 |
|
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M; STELLAIR investigators. Eur Respir J. 2018 May 10;51(5):1702523. doi: 10.1183/13993003.02523-2017. Print 2018 May. PMID: 29545284 |
|
Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X. Eur Respir J. 2018 Nov 29;52(5):1801393. doi: 10.1183/13993003.01393-2018. Print 2018 Nov. PMID: 30309978 |
|
The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. Djukanovic R, Adcock IM, Anderson G, Bel EH, Canonica GW, Cao H, Chung KF, Davies DE, Genton C, Gibson-Latimer T, Hamerlijnck D, Heuvelin E, Louis R, Korn S, Kots M, Kwon N, Naddaf R, Wagers SS; SHARP Clinical Research Collaboration; Members of the CRC-SHARP 💥. Eur Respir J. 2018 Nov 29;52(5):1801671. doi: 10.1183/13993003.01671-2018. Print 2018 Nov. PMID: 30498052 |
|
CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients. Brosseau C, Durand M, Colas L, Durand E, Foureau A, Cheminant MA, Bouchaud G, Castan L, Klein M, Magnan A, Brouard S. Front Immunol. 2018 Dec 21;9:3034. doi: 10.3389/fimmu.2018.03034. eCollection 2018. PMID: 30622536 |
|
Clinical and economic burden of severe asthma: A French cohort study. Nordon C, Grimaldi-Bensouda L, Pribil C, Nachbaur G, Amzal B, Thabut G, Marthan R, Aubier M; COBRA Study Group 💥. Respir Med. 2018 Nov;144:42-49. doi: 10.1016/j.rmed.2018.10.002. Epub 2018 Oct 2. PMID: 30366583 |
|
Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel. Bonta PI, Chanez P, Annema JT, Shah PL, Niven R. Respiration. 2018;95(5):289-300. doi: 10.1159/000488291. Epub 2018 Apr 17. PMID: 29669351 |
|
Factors associated with daily life physical activity in patients with asthma. Hennegrave F, Le Rouzic O, Fry S, Behal H, Chenivesse C, Wallaert B. Health Sci Rep. 2018 Aug 15;1(10):e84. doi: 10.1002/hsr2.84. eCollection 2018 Oct. PMID: 30623040 |
|
[Is celecoxib a safe alternative for the Fernand Widal syndrome?]. Schaller A, Metz-Favre C, Guenard-Bilbaut L, De Blay F. Rev Mal Respir. 2018 Feb;35(2):149-159. doi: 10.1016/j.rmr.2017.09.007. Epub 2018 Feb 17. PMID: 29463423 |
|
[Patients in the IDEAL cohort: A snapshot of severe asthma in France]. Taillé C, Pison C, Nocent C, Devouassoux G, Prud'homme A, Gruber A, Gunsoy N, Albers F. Rev Mal Respir. 2019 Feb;36(2):179-190. doi: 10.1016/j.rmr.2018.10.005. Epub 2018 Nov 11. PMID: 30429093 |
💥 Membre CRISALIS inclus dans la "SHARP Clinical Research Collaboration" : Pr A. Bourdin
💥 Membres CRISALIS inclus dans le "COBRA Study Group" : Pr C. Taillé, Pr P. Berger, Pr A. Bourdin, Dr I. Vachier, Pr P. Chanez, Pr A. Didier, Pr F. De Blay, Pr M. Humbert, Pr G. Garcia, Pr A. Magnan, Pr C. Chenivesse, Pr G. Devouassoux.
